Johnson & Johnson names Ryan Koors VP, Investor Relations

Key highlights
  • Ryan Koors is appointed VP, Investor Relations effective May 7, 2026.
  • He will report to CFO Joseph J. Wolk and succeeds Darren Snellgrove, who is leaving to become CFO of Halozyme.
  • Koors has 20+ years at the company in finance leadership across Innovative Medicine R&D, MedTech surgery and supply chain, most recently serving as CFO/VP Finance for Innovative Medicine Global R&D.

Appointment

Ryan Koors will become Vice President, Investor Relations at Johnson & Johnson, effective May 7, 2026; he will report to Executive Vice President and Chief Financial Officer Joseph J. Wolk.

Succession

Koors succeeds Darren Snellgrove, who is leaving to become chief financial officer of Halozyme.

Background

Koors has more than 20 years at Johnson & Johnson in senior finance roles across Innovative Medicine, Global Research & Development, MedTech surgery and supply chain; he most recently served as Chief Financial Officer and Vice President of Finance for Innovative Medicine Global R&D. He joined the company in 2002 and holds a bachelor’s degree in finance from Wright State University and an MBA from Xavier University.

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

5 November 2026
Johnson & Johnson wins FDA accelerated approval for RYBREVANT FASPRO in recurrent/metastatic HNSCC

Subcutaneous bispecific (amivantamab + hyaluronidase) approved for adults with recurrent/metastatic head and neck squamous cell carcinoma after platinum and anti‑PD‑(L)1 therapy.

23 September 2026
Johnson & Johnson: Model suggests Tec‑Dara may normalize long‑term mortality in early‑line RRMM

Modeling of MajesTEC‑3 trial data estimates a high cure fraction and nearly fourfold median OS benefit for teclistamab plus daratumumab FASPRO versus standard care in relapsed/refractory myeloma.

11 September 2026
Johnson & Johnson: RYBREVANT OS and tolerability updates at WCLC 2026

Final overall survival data for RYBREVANT plus chemotherapy in EGFR exon 20 insertions and tolerability updates for subcutaneous RYBREVANT FASPRO with prophylactic strategies.

30 July 2026
Johnson & Johnson: FDA Priority Review for potential first-in-class subcutaneous RYBREVANT FASPRO in recurrent/metastatic HNSCC

OrigAMI-4 showed 42% response rate with >1/3 complete responses; FDA review shortened to ~6 months; drug targets EGFR and MET and is co-formulated with hyaluronidase.

26 June 2026
Johnson & Johnson: CHMP recommends TECVAYLI plus daratumumab for relapsed/refractory multiple myeloma

CHMP recommendation follows MajesTEC-3 Phase 3 data showing HR 0.17 for PFS and HR 0.46 for OS at ~3 years in adults with RRMM after ≥1 prior therapy, with manageable safety.